newsfilter
← Latest News
PR Newswire·

Braxia Scientific Reports First Quarter 2022 Financial Results; Company Achieves 80% Revenue Growth from Expanding Clinic Patient Base

Revenue from four Canadian clinics increased 80.3% to $407,075 year-over-year Exceeding monthly IV Ketamine infusion targets, ramping up infusions at new Montreal clinic Advancing three funded clinical trials through Braxia Scientific's network of c